Barrington analyst Michael Petusky maintained a Buy rating on Haemonetics Corp (NYSE: HAE) today and set a price target of $118. The company’s shares closed yesterday at $101.77, close to its 52-week high of $108.37.
Petusky wrote:
“We think a solid Q2 would likely result in raised FY/19 numbers.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 15.3% and a 58.9% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
Currently, the analyst consensus on Haemonetics Corp is a Moderate Buy with an average price target of $122.50, which is a 20.4% upside from current levels. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $120 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $108.37 and a one-year low of $41.10. Currently, Haemonetics Corp has an average volume of 766.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.
